Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
List view / Grid view
The first trial participant has been given INO-4500 in Ghana - INO-4500 is a DNA vaccine candidate being developed to protect against Lassa fever.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
20 June 2016 | By Victoria White, Digital Content Producer
Inovio and GeneOne Life Science have received approval to initiate a Phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700)...
30 March 2016 | By Victoria White
Inovio’s Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its Phase I study of 75 healthy subjects...
6 November 2015 | By Victoria White
Immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18...
Results from Inovio’s Phase 2b trial with VGX-3100 in treating women with high grade cervical neoplasia have been published.
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...